<DOC>
	<DOCNO>NCT02500147</DOCNO>
	<brief_summary>This project , `` A double-blind placebo-controlled randomized clinical trial assess efficacy metformin hepatic fat adolescent young adult polycystic ovary syndrome '' , propose explore use novel noninvasive methodology at-risk adolescent young adult population polycystic ovary syndrome ( PCOS ) may gain long-term health benefit early detection treatment non-alcoholic fatty liver disease ( NAFLD ) . PCOS common condition frequently present adolescence young adulthood define elevate androgen ( male hormone ) blood lead 1. hirsutism acne 2. menstrual abnormality amenorrhea . Affected individual increase risk develop insulin resistance ( precursor diabetes ) , NAFLD lipid ( cholesterol ) abnormalities.These feature associate metabolic syndrome , rise major public health concern . Recently , association PCOS NAFLD note superficially study adolescent young adult population . The susceptibility certain PCOS patient develop NAFLD theorize due underlying insulin resistance , elevate androgen level , genetic predisposition . Metformin insulin sensitize medication widely use treat type 2 diabetes mellitus may beneficial effect insulin resistance-related condition include PCOS NAFLD . Although widely use PCOS , effect NAFLD group previously study . The primary aim proposal : 1 ) To determine whether PCOS liver fat &gt; /=4.8 % treated metformin six month decline percentage liver fat compare placebo group . 2 ) To measure association PNPLA3 I148M allele NAFLD PCOS baseline ( n=40 ) . 2b ) To measure association percentage liver fat biomarkers NAFLD , dyslipidemia , insulin resistance body composition baseline ( n=40 ) placebo-controlled intervention metformin PCOS liver fat &gt; 4.8 % ( n=20 ) . The goal research proposal explore use novel noninvasive technology young risk population . Dr. Sopher hop use result research lay groundwork prevention treatment NAFLD metabolic disorder adolescent young adult PCOS prevent lifelong morbidity associate PCOS .</brief_summary>
	<brief_title>Metformin Ectopic Fat Deposition Metabolic Markers Polycystic Ovary Syndrome ( PCOS )</brief_title>
	<detailed_description>PCOS subject screen questionnaire eligibility goal recruit 40 subject 14 25 year , BMI 10th 95th percentile age ( &lt; 20 year ) 18.5 - 29.9 kg/m2 ( 20 year old ) , least two year post-menarche . Oligomenorrheic subject complete protocol early follicular phase menstrual cycle ( day one seven ) amenorrheic subject complete protocol day . The protocol comprise : ) History physical exam : Height , weight , body mass index ( BMI ) ( percentile z-score &lt; 20 year ) , blood pressure , physical exam , Ferriman-Gallwey hirsutism scoring , smoking , alcohol family history ; b ) Laboratory evaluation 0800 0900 overnight fast via 21 gauge intravenous catheter : 1 ) General endocrine panel : Thyroid function , prolactin , 17-hydroxyprogesterone ; 2 ) PCOS panel : luteinizing hormone ( LH ) , follicle stimulate hormone ( FSH ) , estradiol , sex hormone bind globulin , testosterone , free testosterone , androstenedione , dehydroepiandrosterone ; 3 ) Liver panel : Liver enzyme ( alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma glutamyl-transpeptidase ( GGT ) ) , apoptosis marker ( Fas , cytokeratin-18 fragment , M30 ) , pancreatic polypeptide ; 4 ) Cardiovascular risk panel : Cholesterol , triglyceride , HDL , LDL , free fatty acid , c-reactive protein ; 5 ) IR evaluation : hemoglobin A1C , glucose , insulin , c-peptide two-hour oral glucose tolerance test ( OGTT ) 75 gram glucose challenge measurement glucose insulin 30 , 60 , 90 120 minute . IR determine age- BMI- specific homeostatic measure insulin resistance ( HOMA-IR ) cutoff base National Health Nutrition Examination Survey ( NHANES ) study 1,164 nonobese adolescent 12 19 year old . Other IR index evaluate whole body insulin sensitivity ( WBIS ) insulin area curve ; 6 ) Genetic evaluation : A blood sample PNPLA3 I148M allele ( baseline ) . c ) Magnetic resonance spectroscopy ( MRS ) liver intrahepatic lipid content acquire use standard point resolve spectroscopy sequence ( PRESS ) . Percentage liver fat calculate . ) Total body magnetic resonance imaging ( MRI ) 10 mm slice 40 mm interslice gap total body adipose tissue VAT . e ) Dual-energy x-ray absorptiometry ( DXA ) : Total body DXA perform total body lean fat mass percentage body fat . f ) Randomization : Subjects whose liver fat 4.8 % great ( nâ‰ˆ20 ) randomize placebo extended-release metformin 1000 mg ( 2 tablet ) daily . Randomization double-blind perform randomly select permuted size 2 size 4 block determine Columbia University Medical Center ( CUMC ) Research Pharmacy guidance statistician . g ) Intervention : All subject receive identically appear pill bottle label `` Study Medication '' contain first three-month supply either metformin placebo . Subjects instruct take pill dinner take one pill day one week subsequently two pill day remainder first three month . Subjects ask call side effect may experience . They receive weekly call research coordinator ask bring empty pill bottle follow-up study ensure compliance . h ) Brief interim evaluation : After three month intervention phase , subject see general health assessment , include weight , blood pressure physical examination , receive second three-month supply assign intervention . ) Follow-up exam : At end six month , subject undergo laboratory body composition test identical perform baseline testing .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy adolescent girl young woman 13 25 year old At least 2 year postmenarche With clinical hyperandrogenism and/or hyperandrogenemia , menstrual dysfunction ( oligomenorrhea amenorrhea ) exclusion know disorder . PCOS diagnose use NIH 1990 criterion . Past present history medical disorder medication know affect body composition Insulin secretion sensitivity , GHIGFI axis ( e.g . steroid hormone thyroid replacement ) Any disease affect bone metabolism ( collagen disorder , primary hyperparathyroidism , nephrolithiasis , untreated hyperthyroidism ) indwell hardware History current past pregnancy Hormonal contraceptive metformin use within 3 month enrollment Nonclassical congenital adrenal hyperplasia ( CAH ) early morning 17hydroxyprogesterone level less 200 ng/dL</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Polycystic Ovary Syndrome</keyword>
	<keyword>Non-Alcoholic Fatty Liver Disease</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Young Women</keyword>
	<keyword>MRI</keyword>
	<keyword>MRS</keyword>
	<keyword>DXA</keyword>
	<keyword>PNPLA3</keyword>
	<keyword>Metformin</keyword>
	<keyword>Randomized Clinical Trial</keyword>
	<keyword>Placebo</keyword>
	<keyword>Hirsutism</keyword>
	<keyword>Acne</keyword>
	<keyword>Amenorrhea</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Percentage liver fat</keyword>
</DOC>